GlassScriptPhysician profile
Rachel Koller
NPI 1821843079
$5,170.27
in general payments reported to CMS, 2019-2025
23 companies · $4,236 in 2025
The $4,236 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $934 · 2025: $4,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,170.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $543.56 | 2024-2025 | Dupixent |
| Genzyme Corporation | $463.01 | 2024-2025 | |
| Abbvie INC. | $454.67 | 2025 | |
| Janssen Biotech, INC. | $438.91 | 2024-2025 | Tremfya |
| Ucb, INC. | $385.71 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $351.10 | 2024-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $279.91 | 2024-2025 | |
| Incyte Corporation | $263.68 | 2024-2025 | Opzelura, Jakafi |
| Dermavant Sciences, INC. | $262.74 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $235.56 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $214.46 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.10 | 2025 | Jublia |
| Arcutis Biotherapeutics, INC. | $172.28 | 2024-2025 | Zoryve |
| Organon LLC | $169.93 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $164.11 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $159.10 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $106.86 | 2024-2025 | Otezla |
| Mayne Pharma Commercial LLC | $105.44 | 2025 | |
| Galderma Laboratories, L.P. | $72.23 | 2025 | Nemluvio |
| Almirall LLC | $47.70 | 2024-2025 | Klisyri, Seysara |
| Pfizer INC. | $44.94 | 2025 | |
| Botanix Sb INC | $16.39 | 2025 | Sofdra |
| Kerecis Limited | $11.88 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Koller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.